ImmunityBio Inc (IBRX)

ImmunityBio's stock experienced significant volatility over the past six months. In November 2025, the company reported strong Q3 financial results with a 434% increase in product revenue. In January 2026, preliminary full-year revenue was announced at $113 million, a 700% increase year-over-year, and ANKTIVA received approval in Saudi Arabia. February 2026 saw a 700% increase in net product revenue and conditional marketing authorization in Europe, causing a stock surge. In March 2026, the stock dropped 20% after an FDA warning letter regarding misleading statements in advertising. In April 2026, the company responded to the FDA and reported preliminary Q1 revenue of $44.2 million, a 168% increase. In May 2026, the company presented new data and reported Q1 revenue of $44.2 million, but the stock declined due to bearish sentiment and class-action lawsuits.

Based on the available information, there is no indication of significant demand seasonality for ImmunityBio, Inc.'s products and services. The company has reported consistent and strong demand for its lead immunotherapy, ANKTIVA, with increasing unit sales volume and net product revenue quarter-over-quarter since its commercial launch. The demand is driven by clinical adoption and expansion into new markets and indications, rather than seasonal fluctuations.

ImmunityBio, Inc. is a commercial-stage biotechnology company focused on developing next-generation immunotherapies to activate the patient's immune system against cancer and infectious diseases. Their lead product, ANKTIVA, is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer and has received approval in Saudi Arabia for metastatic non-small cell lung cancer. The company is also advancing its Cancer BioShield platform, positioning ANKTIVA as a backbone for targeting various tumor types.

ImmunityBio has established a global commercial footprint with regulatory authorizations for ANKTIVA in 33 countries across the US, UK, EU, and Saudi Arabia. The company has formed partnerships with Accord Healthcare in Europe and BioPharma & Cigalah in the Middle East. They have established subsidiaries in Dublin and Riyadh to support launches in Europe and the MENA region, respectively. ANKTIVA recently gained conditional approval across 27 EU countries, along with Iceland, Liechtenstein, and Norway. The company operates in the United States and Europe, with the majority of its revenue currently coming from the United States.

ImmunityBio's brand reputation has been influenced by both positive commercial advancements and regulatory challenges. The rapid global expansion and regulatory approvals of ANKTIVA, along with strong financial performance, have bolstered the company's image. However, an FDA warning letter in March 2026 regarding misleading statements about ANKTIVA led to a stock price drop and securities class action lawsuits. The company has responded to the FDA and implemented enhanced advertising compliance measures.

ImmunityBio is owned by a mix of institutional shareholders (16.79%), company insiders (7.45%), and retail investors (76.08%). There are 347 institutional owners holding 209,747,711 shares. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. Patrick Soon-Shiong, the founder and executive chairman, is the largest individual shareholder, owning 70.34 million shares, representing 6.84% of the company.